A. Mitchell

发表

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, A. Nicholson, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cure-Rate Survival Models and Their Application to Cancer Clinical Trials

B. Barlogie, G. Morgan, M. Othus, 2017 .

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

J. Crowley, B. Barlogie, E. Tian, 2016, Blood Cancer Journal.

Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma

B. Barlogie, G. Morgan, M. Zangari, 2016, Clinical Cancer Research.

FAILURE TO ENTER PATIENTS TO RANDOMISED STUDY OF SURGERY FOR BREAST CANCER

A. Mitchell, M. Lucas, E. G. Lee, 1984, The Lancet.

The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification

Fergus Gleeson, Heber MacMahon, Jin Mo Goo, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Reply to the Letter to the Editor by Hendriks et al.

R. Rami-Porta, W. Eberhardt, A. Mitchell, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

J. Crowley, B. Barlogie, E. Tian, 2016, Blood cancer journal.

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

B. Barlogie, F. van Rhee, Y. Alsayed, 2012, Haematologica.

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Patricia A. H. Williams, Steve B Jones, K. Y. Wong, 2021, The Lancet.

Curing Multiple Myeloma (MM) with Total Therapy (TT)

B. Barlogie, G. Morgan, M. Zangari, 2014 .

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Steve B Jones, K. Y. Wong, Chamil H. Hettiarachchi, 2021, Lancet.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Drew M. Pardoll, Janis M. Taube, Paul T. Nghiem, 2016, The New England journal of medicine.

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

J. Crowley, R. Rami-Porta, A. Turrisi, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, N. Girard, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, N. Girard, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study

Samuel G. Armato, David P. Naidich, Alan Mitchell, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the Staging Project Database of the International Association for the Study of Lung Cancer

R. Rami-Porta, D. Ball, A. Mitchell, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.

David C Rice, David Naidich, Joseph Friedberg, 2016, The Annals of thoracic surgery.

Optimal Three-Group Splits Based on a Survival Outcome

B. Barlogie, G. Morgan, J. Crowley, 2017 .

Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants

B. Barlogie, G. Morgan, E. Tian, 2016, Clinical Cancer Research.

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.

B. Barlogie, E. Anaissie, T. Bartel, 2013, Blood.

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

B. Barlogie, Y. Alsayed, J. Crowley, 2013, Leukemia.

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

J. Crowley, B. Barlogie, E. Tian, 2016, Blood Cancer Journal.

Curing myeloma at last: defining criteria and providing the evidence.

B. Barlogie, G. Morgan, J. Epstein, 2014, Blood.

Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma

B. Barlogie, D. Johann, F. van Rhee, 2013, Haematologica.

Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data

B. Barlogie, E. Anaissie, J. Epstein, 2013, Haematologica.

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

B. Barlogie, G. Morgan, M. Zangari, 2015 .

Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents

Antje Hoering, Michael LeBlanc, Alan Mitchell, 2013, Clinical trials.